EFFICACY OF TRIMETAZIDINE IN CHRONIC STABLE ANGINA PATIENTS RECEIVING MAXIMALLY-TOLERATED BACKGROUND MEDICAL THERAPY

Authors

  • Samar Arfeen Punjab Institute of Cardiology, Lahore
  • Ch Muhammad Umer Razaq Mayo Hospital, Lahore, Pakistan
  • Muhammad Ejaz Punjab Institute of Cardiology, Lahore
  • Zeeshan Malik Punjab Institute of Cardiology, Lahore
  • Sadia Nasim Punjab Institute of Cardiology, Lahore
  • Fida Muhammad SMC, Sargodha, Pakistan

Keywords:

Angina, Placebo, Trimetazidine, shorter duration

Abstract

ABSTRACT
BACKGROUND: There are many presentations of coronary artery disease. Out of which chronic stable angina is one variety. This study was designed to see the effectiveness of trimetazidine as an anti angina option.
OBJECTIVE: To compare the frequency of angina attacks per week in patients using Trimetazidine vs Placebo.
MATERIAL & METHODS: This Randomized controlled trial was carried out in Out Patient Department, Punjab Institute of Cardiology, Lahore from 04-09-2017 to 04-03-2018 after approval from ethical committee. After written and informed consent 256 patients fulfilled selection criteria were enrolled and two equal groups were made. Group one was treated with Trimetazidine and control was treated with their previous medicine and placebo and assessed for number of anginal attacks per week. The collected data was analysed by SPSS.
RESULTS:The mean age of patients was 49.5±6.8years. There were 150 (58.5%) males and 106 (41.5%) females. The mean attack of angina in TMZ group reduced from 5.06± 2.03 (p value 0.15) to 3.6 ±2.2 (p value 0.000) in TMZ group as compared to placebo group i.e 5.5±3 to 5.4±2.6 and it was more effective with shorter duration of disease.
CONCLUSION: It has been concluded that the frequency of angina attack reduced in patients using trimetazidine.
KEY WORDS: Angina, Placebo, Trimetazidine, shorter duration

Published

2021-04-24